<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937140</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-06-11</org_study_id>
    <nct_id>NCT04937140</nct_id>
  </id_info>
  <brief_title>Assessment of 14-3-3 η (Eta) Protein Antibodies in the Serum of Rheumatoid Arthritis Patients and Its Relation to Atherosclerosis.</brief_title>
  <official_title>14-3-3 η (Eta) Protein as a Marker of Disease Activity, Severity and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are: • To assess 14-3-3 η (eta) protein antibodies in the serum of&#xD;
      rheumatoid arthritis patients and its relation to disease activity and severity. • To&#xD;
      investigate the role of 14-3-3 η (eta) protein in the diagnosis or assessment of subclinical&#xD;
      carotid artery atherosclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients will be interviewed for demographic and clinical data (age, sex, occupation,&#xD;
      age at onset of the disease, joints affected, extra-articular features, disease duration,&#xD;
      family history and treatment regimen). • Assessment of medical and rheumatologic history.&#xD;
&#xD;
        -  Careful general and musculoskeletal examination.&#xD;
&#xD;
        -  Assessment of disease activity will be performed using the Disease Activity Score&#xD;
           (DAS28) including 28 tender and swollen joint count, ESR and visual analogue scale.&#xD;
&#xD;
        -  X-ray both hands and feet&#xD;
&#xD;
        -  Larsen Score&#xD;
&#xD;
        -  Assessment of Body Mass Index (BMI)&#xD;
&#xD;
        -  Laboratory investigations:&#xD;
&#xD;
        -  Complete blood count (CBC) • Rheumatoid factor (RF) by latex method • Anti citrullinated&#xD;
           protein antibodies ACPA by enzyme-linked immunosorbent assay (ELISA) • 14-3-3 η (eta)&#xD;
           protein by (ELISA) • Erythrocytic sedimentation rate (ESR) • Quantitative C-reactive&#xD;
           protein (CRP) • fasting blood glucose • lipid profile • Carotid Doppler ultrasound (for&#xD;
           measurement of carotid intima media thickness and detection of plaques) • ECG&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>14-3-3 eta protein as measured by enzyme-linked immunosorbent assay (ELISA) in the serum of the participants and carotid intima media thickness as determined by carotid doppler ultrasound</measure>
    <time_frame>through study completion, an average of 1 year&quot;</time_frame>
    <description>relation between presence of 14-3-3 η (eta)by enzyme-linked immunosorbent assay (ELISA) in the serum of the participants and carotid intima media thickness and detection of plaques</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>rheumatoid arthritis patients</arm_group_label>
    <description>90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>50 age and sex matched healthy controls. All</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients</intervention_name>
    <description>assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>rheumatoid arthritis patients</arm_group_label>
    <other_name>Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include 90 RA patients diagnosed according to the American college of&#xD;
        rheumatology (ACR) -EULAR RA classification criteria 2010 in addition to 50 age and sex&#xD;
        matched healthy controls.&#xD;
&#xD;
        All the patients will be recruited from Rheumatology and Rehabilitation outpatient clinic&#xD;
        in Sohag University Hospitals, Faculty of Medicine .&#xD;
&#xD;
        Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               1. Patients with RA classified according to the revised American College of&#xD;
                  Rheumatology (ACR)/EULAR RA classification criteria 2010 for RA.&#xD;
&#xD;
               2. Age ≥ 18 years.&#xD;
&#xD;
               3. Patients who are able and willing to give written informed consent.&#xD;
&#xD;
               4. Disease duration more than one year&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
               1. Any other autoimmune disease rather than RA.&#xD;
&#xD;
               2. Patients with any disease affecting the cardiovascular system other than RA.&#xD;
&#xD;
               3. Patients with known risk factors for atherosclerosis as diabetes, hypertension,&#xD;
                  hyperlipidemia and obesity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>doaa adel, specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>In the Medical Administration Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>doaa adel, specialist</last_name>
    <phone>01201786669</phone>
    <email>doaa_adel_post@med.sohag.edu.eg</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Doaa Adel Ibrahim</investigator_full_name>
    <investigator_title>Specialist of Rheumatology &amp; Rehabilitation In the Medical Administration Sohag Universit</investigator_title>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

